INAB Stock Overview
IN8bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of solid and liquid tumors.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
IN8bio, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.06 |
| 52 Week High | US$3.48 |
| 52 Week Low | US$0.65 |
| Beta | -0.0080 |
| 1 Month Change | -11.67% |
| 3 Month Change | -18.46% |
| 1 Year Change | -45.64% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -89.40% |
Recent News & Updates
Recent updates
We're Keeping An Eye On IN8bio's (NASDAQ:INAB) Cash Burn Rate
Apr 03
Companies Like IN8bio (NASDAQ:INAB) Could Be Quite Risky
Nov 04Is IN8bio (NASDAQ:INAB) In A Good Position To Invest In Growth?
Jan 26Here's Why We're Watching IN8bio's (NASDAQ:INAB) Cash Burn Situation
Oct 12IN8bio gains 53% as H.C. Wainwright initiates with Buy
Aug 30IN8bio raises additional funds from underwriter of stock offering
Aug 19IN8bio prices $10.25M stock offering
Aug 12We're Keeping An Eye On IN8bio's (NASDAQ:INAB) Cash Burn Rate
Jun 04IN8bio (NASDAQ:INAB) Is In A Good Position To Deliver On Growth Plans
Feb 13IPO Update: IN8bio Aims For Downsized IPO
Jul 29Shareholder Returns
| INAB | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 6.0% | 1.0% | 1.2% |
| 1Y | -45.6% | 0.7% | 24.9% |
Return vs Industry: INAB underperformed the US Biotechs industry which returned 1.1% over the past year.
Return vs Market: INAB underperformed the US Market which returned 24.7% over the past year.
Price Volatility
| INAB volatility | |
|---|---|
| INAB Average Weekly Movement | 10.3% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: INAB's share price has been volatile over the past 3 months.
Volatility Over Time: INAB's weekly volatility has decreased from 18% to 10% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 31 | William Ho | in8bio.com |
IN8bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of solid and liquid tumors. Its lead product candidates include INB-400, which is in Phase 2 clinical trial to treat newly diagnosed glioblastoma (GBM); INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of GBM and other cancers; and INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with hematologic malignancies undergoing hematopoietic stem cell transplantation. The company develops INB-300 and INB-500 that are in preclinical phase for treatment of acute myeloid leukemia, and other solid and hematological tumor types.
IN8bio, Inc. Fundamentals Summary
| INAB fundamental statistics | |
|---|---|
| Market cap | US$45.02m |
| Earnings (TTM) | -US$30.01m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-1.5x
P/E RatioIs INAB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| INAB income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$30.01m |
| Earnings | -US$30.01m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.69 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did INAB perform over the long term?
See historical performance and comparison